Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
NCT06543108
Summary
This project aims to comprehensively analyze the diagnostic efficacy of SUVmax, SUVean, TLG, MTV, etc. in gastric cancer through 18F-FAPI-04 PET/CT imaging combined with serum tumor markers and other methods, and construct a molecular imaging diagnostic model for gastric cancer; Next, analyze the diagnostic efficacy of 18F-FAPI-04 PET/CT and PET/MR multimodal imaging in evaluating SUVmax, PET/CT-PCI, and PET/MR-PCI for gastric cancer peritoneal metastasis, and construct a molecular imaging diagnostic model for gastric cancer peritoneal metastasis; Exploring the clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer.
Eligibility
Inclusion Criteria: 1. Age over 18 years old; 2. Diagnosed as a patient with gastric cancer; 3. Receive FAPI PET/CT and FDG PET/CT imaging within one week; 4. Perform serum tumor marker testing one week before and after scanning Exclusion Criteria: 1. History of other malignant tumors; 2. Patients with severe infections, severe underlying diseases such as heart, kidney, and liver; 3. Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination; 4. Patients with unorganized pathology or incomplete clinical data
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06543108